MECFA Blog

News & Articles

The search for molecular glue in targeted disease control

In cells, there are proteins that do the work and proteins that regulate them. The latter inhibit or enhance activity, depending on the need. However, in many diseases—for example cancer—there is so much overactivity in the cell that the regulator proteins can no longer keep up with it. Researchers at Eindhoven University of Technology therefore developed a kind of molecular "glue" in 2019 that helps the regulator to inhibit faster. Now this technique has been further developed, and the researchers have found a completely unexpected way to look for new protein-gluing molecules. This offers prospects for the development of drugs for cancer, diabetes or cystic fibrosis, for example. They publi

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

One year of vest therapy with high frequency chest wall oscillation (HFCWO) can reduce the risk of hospitalization and the use of antibiotics, while improving self-reported respiratory health in people with non-cystic fibrosis bronchiectasis (NCFB), according to a study based on patient registry data. The study, “Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasis,” was published in the journal Therapeutic Advances in Respiratory Disease. A research grant supporting this study was given by RespirTech (a Phillips company), which markets a system for HFCWO. HFCWO is a technique for clearing airway mucus, which involves

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p

Researchers at Harvard University announced this week it will begin examining if an existing drug used to treat cystic fibrosis could provide benefits to patients with severe cases of coronavirus. Harvard will conduct the research in partnership with Boston Children’s Hospital and Brigham and Women’s Hospital. The focus for researchers is Dornase alfa, also known as DNase 1 or Pulmozyme. It is FDA-approved to help patients with cystic fibrosis and is meant to break up thick mucus secretions and prevent lung infections. The drug may also break up neutrophil extracellular traps, or NETs, which scientists believe contribute to lung inflammation, Harvard said. The promise of the drug pertaining

Eleven medicines backed for EU approval

The European Medicines Agency human medicines committee (CHMP) has backed eleven medicines for approval at its July 2020 meeting, including a medicine for use in countries outside the region and a novel treatment for multiple myeloma. The Dapivirine Vaginal Ring (dapivirine), developed by the International Partnership for Microbicides Belgium to reduce the risk of infection with HIV-1 in combination with safer sex practices when oral pre-exposure prophylaxis is not used, is the eleventh medicine recommended by EMA under EU Medicines for all (EU-M4All), a mechanism that allows the CHMP to assess and give opinions on medicines that are intended for use in countries outside the EU. In some area

Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis L

Neutrophil elastase (NE) is a major protease in the airways of patients with cystic fibrosis (CF) that activates airway inflammation by several mechanisms. NE stimulates epithelial toll like receptors (TLR) resulting in cytokine upregulation and release, upregulates MUC5AC, a major airway mucin, degrades both phagocytic receptors and opsonins resulting in both neutrophil and macrophage phagocytic failure, generates oxidative stress extracellular generation and uptake of heme free iron, and activates other proteases. Altogether, these mechanisms create a significant inflammatory challenge that impairs innate immune function and results in airway remodeling. Currently, a major gap in our thera

Urine Marker Could Help in Screening for CF Lung Infections, Study Finds

Measuring levels of a molecule called lipoarabinomannan, or LAM, in a person’s urine could be an easier way of screening for airway infections due to nontuberculous mycobacteria in people with cystic fibrosis (CF), a study suggests. The study, “Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway,” was published in the Journal of Cystic Fibrosis. Nontuberculous mycobacteria (NTM) are bacteria from the genus mycobacteria other than Mycobacterium tuberculosis, which causes tuberculosis, and Mycobacterium leprae, which causes leprosy. NTM can cause infections in people, particularly in those with pre-existing lung conditions. CF patients are at risk of NTM infectio

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean